{'52WeekChange': -0.38,
 'SandP52WeekChange': 0.0644362,
 'address1': '6200 Lookout Road',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 1.23,
 'askSize': 1100,
 'averageDailyVolume10Day': 8540800,
 'averageVolume': 2836963,
 'averageVolume10days': 8540800,
 'beta': 2.118627,
 'beta3Year': None,
 'bid': 1.22,
 'bidSize': 4000,
 'bookValue': 0.509,
 'category': None,
 'circulatingSupply': None,
 'city': 'Boulder',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 1.61,
 'dayLow': 1.21,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.043,
 'enterpriseToRevenue': 7.603,
 'enterpriseValue': 37384912,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '720 643 5201',
 'fiftyDayAverage': 1.0449142,
 'fiftyTwoWeekHigh': 2.27,
 'fiftyTwoWeekLow': 0.311,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 46880568,
 'forwardEps': -0.46,
 'forwardPE': -2.6956522,
 'fromCurrency': None,
 'fullTimeEmployees': 45,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.05658,
 'heldPercentInstitutions': 0.16941999,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1478476800,
 'lastSplitFactor': '1:15',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/miragen.com',
 'longBusinessSummary': 'Miragen Therapeutics, Inc., a clinical-stage '
                        'biopharmaceutical company, engages in discovering and '
                        'developing proprietary RNA-targeted therapies with a '
                        'specific focus on microRNAs and their role in '
                        'diseases where there is a high-unmet medical need. '
                        'Its four lead product candidates include cobomarsen, '
                        'an inhibitor of miR-155 for treating various blood '
                        'cancers, such as cutaneous T-cell lymphoma, adult '
                        'T-cell lymphoma/leukemia, diffuse large B-cell '
                        'lymphoma, and chronic lymphocytic leukemia; '
                        'Remlarsen, a replacement for miR-29, a microRNA that '
                        'is found at abnormally low levels in various '
                        'pathological fibrotic conditions, including cutaneous '
                        'and ocular fibrosis, which is in Phase II clinical '
                        'trial; MRG-229, which is in preclinical trial for the '
                        'treatment of idiopathic pulmonary fibrosis; and MRG- '
                        '110, an inhibitor of miR-92, a microRNA expressed in '
                        'endothelial cells, which has completed two Phase I '
                        'clinical trial for the treatment of heart failure, '
                        'wound healing, and other ischemic disease in the '
                        'United States and Japan. Miragen Therapeutics, Inc. '
                        'was founded in 2006 and is based in Boulder, '
                        'Colorado.',
 'longName': 'Miragen Therapeutics',
 'market': 'us_market',
 'marketCap': 65815852,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_45015663',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -38288000,
 'nextFiscalYearEnd': 1640908800,
 'open': 1.59,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '720 643 5200',
 'previousClose': 1.095,
 'priceHint': 4,
 'priceToBook': 2.4361494,
 'priceToSalesTrailing12Months': 13.385367,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 1.61,
 'regularMarketDayLow': 1.21,
 'regularMarketOpen': 1.59,
 'regularMarketPreviousClose': 1.095,
 'regularMarketPrice': 1.59,
 'regularMarketVolume': 44434796,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 53077300,
 'sharesPercentSharesOut': 0.022,
 'sharesShort': 1169546,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 321923,
 'shortName': 'Miragen Therapeutics, Inc.',
 'shortPercentOfFloat': 0.0222,
 'shortRatio': 0.35,
 'startDate': None,
 'state': 'CO',
 'strikePrice': None,
 'symbol': 'MGEN',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.094,
 'twoHundredDayAverage': 0.8020288,
 'volume': 44434796,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.miragen.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '80301'}